Sermorelin
Medium EvidenceA GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment.
What It Is
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of GHRH. It was previously FDA-approved under the brand name Geref for diagnosing and treating growth hormone deficiency in children. It stimulates the pituitary to release growth hormone in a pulsatile, physiological manner. Though the branded product was discontinued, it remains available through compounding pharmacies. In 2026, sermorelin continues to be one of the most commonly prescribed GHRH analogs at anti-aging and hormone optimization clinics, valued for its physiological pulsatile GH release pattern and established safety profile. It is frequently combined with ipamorelin (a GHRP) in clinical protocols to synergistically enhance GH output while minimizing cortisol and prolactin elevation. Sermorelin's shorter half-life compared to CJC-1295 (DAC) is viewed as both a limitation and an advantage — it better mimics the body's natural GH pulsatility. On April 15, 2026, the FDA removed sermorelin from Category 2 as part of a broader reclassification of 12 peptides, reinstating its eligibility for 503A bulk compounding under physician prescription. This regulatory shift followed HHS Secretary Robert F. Kennedy Jr.'s February 2026 announcement that most peptides placed on the Category 2 list in 2023 would be moved back to Category 1. In June 2026, telehealth company Noom finalized its acquisition of Tailor Made Compounding, a licensed 503A compounding pharmacy operating in 46 states, and announced plans to add sermorelin to its prescription formulary as part of an expansion into healthy-aging services — a sign that major consumer telehealth platforms are building regulated peptide supply chains ahead of the FDA's July 2026 PCAC compounding review.
Regulatory Status
Removed from Category 2 on April 15, 2026 as part of FDA reclassification of 12 peptides. Now eligible for 503A compounding with valid prescription. Previously FDA-approved under brand name Geref (discontinued).
Effective: April 15, 2026
View FDA SourceEvidence Snapshot
Commonly Discussed Benefits
Researching Sermorelin? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Previously FDA-approved; branded product discontinued
- Available through compounding pharmacies with prescription
- Shorter half-life than newer GHRH analogs
- Requires medical supervision
Comparisons
See how Sermorelin compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Walker RF. — Sermorelin: a better approach to management of adult-onset growth hormone insufficiency. Clin Interv Aging. 2006 PubMed
- [2] FDA Announces Change in Status of 12 Peptides - SSRP Institute. April 2026 PubMed
- [3] MobiHealthNews — Noom acquires compounding pharmacy to expand beyond weight loss PubMed
Keep researching in the app
- Log Sermorelin to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
CJC-1295
Medium EvidenceA growth hormone releasing hormone analog studied for stimulating growth hormone secretion.
Ipamorelin
Medium EvidenceA selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
Tesamorelin
High EvidenceA GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy.
CJC-1295 (DAC)
Medium EvidenceA long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification.